Analysed NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS) News Sources
NurExone to Participate in Water Tower Research Insights Conference on April 14, 2026
10-04-2026
yahoo.com
NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization
07-04-2026
yahoo.com
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy
01-04-2026
yahoo.com
NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement
26-03-2026
yahoo.com
NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update
27-02-2026
yahoo.com
NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production
10-02-2026
yahoo.com
NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise
30-01-2026
yahoo.com
What is the current price of NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS)?
The current price of NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS) is $0.47.
NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS) since the previous trading day is $-0.01.
NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS) since the previous trading day is -2.0833%.
What is the most recent average sentiment score for NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS)?
The most recent average sentiment score for NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS) is 87 out of 100.
What is the most recent average sentiment for NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS)?
The most recent sentiment for NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS) is .
SEC-8K** Filing Available For NUREXONE BIOLOGIC INC (NRXBF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.